Literature DB >> 903673

Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine.

D S Burke, H H Ramsburg, R Edelman.   

Abstract

We studied the persistence of antibody to Venezuelan equine encephalomyelitis (VEE) virus subtypes in sera of 20 volunteers inoculated seven or nine years previously with attenuated TC-83 VEE virus vaccine. Serological patterns were compared with those of 10 other persons from whom samples of serum were obtained 28 days after vaccination with TC-83 virus. Vaccines had no other known exposure to a group A arbovirus. Titers of neutralizing antibody of greater than or equal to 1:10 were measured against the homologous TC-83 strain of virus in all long- and short-term vaccinees. In both groups of vaccinees the percentage of antibody-positive persons and their geometric mean titers of antibody to the epizootic subtypes I-A, I-B, and I-C were higher than titers to the enzootic subtypes I-D, I-E, II, III, and IV. However, proportionally fewer long-term vaccinees than short-term vaccinees had detectable neutralizing antibody reactive with enzootic strains. These results reveal long-lasting circulation of neutralizing antibody to TC-83 virus and closely related epizootic variants in 95%-100% of vaccinees. The relatively lower rate of antibody conversion and the loss of antibody to more antigenically remote enzootic subtypes of VEE virus suggest that vaccinees may be less well protected against infection by these strains.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 903673     DOI: 10.1093/infdis/136.3.354

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  The amino-terminal domain of alphavirus capsid protein is dispensable for viral particle assembly but regulates RNA encapsidation through cooperative functions of its subdomains.

Authors:  Valeria Lulla; Dal Young Kim; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

2.  Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses.

Authors:  Slobodan Paessler; Haolin Ni; Olga Petrakova; Rafik Z Fayzulin; Nadezhda Yun; Michael Anishchenko; Scott C Weaver; Ilya Frolov
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV).

Authors:  Donald L Fine; Erin Jenkins; Shannon S Martin; Pamela Glass; Michael D Parker; Brad Grimm
Journal:  J Virol Methods       Date:  2009-11-10       Impact factor: 2.014

4.  Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation.

Authors:  Svetlana Atasheva; Dal Young Kim; Maryna Akhrymuk; David G Morgan; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

5.  A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.

Authors:  N L Davis; K W Brown; R E Johnston
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

7.  Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic.

Authors:  Slobodan Paessler; Rafik Z Fayzulin; Michael Anishchenko; Ivorlyne P Greene; Scott C Weaver; Ilya Frolov
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters.

Authors:  P B Jahrling; E H Stephenson
Journal:  J Clin Microbiol       Date:  1984-03       Impact factor: 5.948

9.  Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge.

Authors:  R M Kinney; J J Esposito; J H Mathews; B J Johnson; J T Roehrig; A D Barrett; D W Trent
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

10.  IRES-based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice.

Authors:  Shannan L Rossi; Mathilde Guerbois; Rodion Gorchakov; Kenneth S Plante; Naomi L Forrester; Scott C Weaver
Journal:  Virology       Date:  2013-01-22       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.